Table 3. Review of Novel Oral Anticoagulant Pharmacokinetics23
CharacteristicsWarfarinDabigatranRivaroxabanApixabanEdoxaban
TargetSynthesis of II, VII, IX, XIIa (thrombin)XaXaXa
Dose (mg)Variable150
110*
75†		20 (15)5 (2.5)30
60
FrequencyOnce a dayTwice a dayOnce a dayTwice a dayOnce a day
Hour to Cmax72–9622–4.51–31–2—
Half-life (hours)4012–145–98–1510–14
>24 if creatinine <309–13 (Elderly)
InteractionsCYP2C9/3A4/1A2P-gPCYP3A4/2J2
P-gP		CYP3A4
P-gP		P-gP
Renal elimination (%)<180332535

  • ↵* The 110-mg dose not available in the United States.

  • ↵† Use 75-mg dose in patients with creatinine clearance 15–30 mL/min.

  • P-gP, P-glycoprotein; CYP, cytochrome P; IIa, factor IIa (thrombin); Xa, factor Xa.